Our corporate governance approach supports our objective of creating long-term value for our company, our shareholders and society. We carefully monitor developments in corporate governance and regularly meet with shareholders to understand their expectations.
Members of the Board of Directors
The Novartis Board of Directors is responsible for the direction, strategy, organization and administration of the company. The Board comprises 12 members with Joerg Reinhardt as chairman.
Joerg Reinhardt, Ph.D.
Chairman of the Board of Directors of Novartis AG
Enrico Vanni, Ph.D.
Vice Chairman of the Board of Directors
Nancy C. Andrews, M.D., Ph.D.
Srikant Datar, Ph.D.
Elizabeth (Liz) Doherty
Frans van Houten
Andreas von Planta, Ph.D.
Charles L. Sawyers, M.D.
William T. Winters
Charlotte Pamer-Wieser, Ph.D.
Executive Committee of Novartis
Under the leadership of Vasant Narasimhan, the Executive Committee of Novartis (ECN) is responsible for overseeing the business operations of Group companies. ECN members are chosen by the Board of Directors.
Vasant (Vas) Narasimhan, M.D.
Chief Executive Officer (CEO) of Novartis
Chief People and Organization Officer of Novartis
Chief Digital Officer of Novartis
James (Jay) Bradner, M.D.
President, Novartis Institutes for BioMedical Research (NIBR)
Chief Financial Officer (CFO) of Novartis
Shannon Thyme Klinger
Group General Counsel of Novartis
Steffen Lang, Ph.D.
Global Head of Novartis Technical Operations (NTO)
Klaus Moosmayer, Ph.D.
Chief Ethics, Risk and Compliance Officer of Novartis
Susanne Schaffert, Ph.D.
CEO, Novartis Oncology
John Tsai, M.D.
Head of Global Drug Development and Chief Medical Officer for Novartis
President, Novartis Pharmaceuticals
Head of Novartis Business Services (NBS)
These materials contain forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 that can generally be identified by words such as “potential,” “expected,” “will,” “planned,” “pipeline,” “outlook,” or similar expressions, or by express or implied discussions regarding potential new products, potential new indications for existing products, potential product launches, or regarding potential future revenues from any such products; or regarding the potential outcome, or financial or other impact on Novartis, of the proposed divestiture of certain portions of our Sandoz Division business in the US; or regarding the potential impact of the share buyback plan; or regarding potential future sales or earnings of the Group or any of its divisions or potential shareholder returns; or by discussions of strategy, plans, expectations or intentions. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. You should not place undue reliance on these statements. In particular, our expectations could be affected by, among other things: global trends toward healthcare cost containment, including ongoing government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; regulatory actions or delays or government regulation generally, including potential regulatory actions or delays with respect to the proposed transactions or the development of the products described in these materials; the potential that the strategic benefits, synergies or opportunities expected from the Alcon and Sandoz transactions may not be realized or may be more difficult or take longer to realize than expected; the inherent uncertainties involved in predicting shareholder returns; the uncertainties inherent in the research and development of new healthcare products, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products that commenced in prior years and will continue this year; safety, quality or manufacturing issues; uncertainties regarding actual or potential legal proceedings, including, among others, product liability litigation, disputes and litigation with business partners or business collaborators, government investigations generally, litigation and investigations regarding sales and marketing practices, and intellectual property disputes; uncertainties involved in the development or adoption of potentially transformational technologies and business models; our performance on environmental, social and governance measures; general political, economic and trade conditions, including uncertainties regarding the effects of ongoing instability in various parts of the world; uncertainties regarding future global exchange rates; uncertainties regarding future demand for our products; uncertainties regarding potential significant breaches of data security or data privacy, or disruptions of our information technology systems; and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in these materials as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.
All product names appearing in italics are trademarks owned by or licensed to Novartis Group companies. Other trademarks are the property of the respective owners.
ments as a result of new information, future events or otherwise.